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Polyarthritis is a common manifestation of rheumatologic disorders; however, paraneoplastic arthropathies also arise as poly-
arthritis or polymyalgia, particularly in patients with myelomas, lymphomas, acute leukemia, and solid tumors. Because para-
neoplastic syndromes, in some instances, might be manifested before a cancer diagnosis, they are difficult to diagnose and are 
often misdiagnosed. We experienced a 63-year-old female patient who had nonspecific arthritis on both hands and feet accom-
panied by fever. She had been diagnosed as rheumatoid arthritis and treated with prednisolone and disease modifying an-
ti-rheumatic drugs (DMARDs) including methotrexate and anti-tumor necrosis factor agents. Her arthritis did not respond with 
anti-rheumatic treatment and diffuse large B-cell lymphoma was diagnosed by bone marrow biopsy. After 6 cycles of chemo-
therapy, her arthritis was improved as well as underlying lymphoma. (J Rheum Dis 2016;23:256-260)
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INTRODUCTION
Polyarticular joint pain poses a diagnostic challenge be-
cause of the extensive differential diagnosis. Polyarthritis 
which affects 5 or more joints is a common manifestation 
of rheumatic diseases characterized with inflammatory 
arthritis such as rheumatoid arthritis (RA) and spondy-
loarthropathy. However, it can be occurred in other dis-
eases such as crystal-induced arthritis, viral infections, or 
malignant tumor [1]. By thorough history and a complete 
physical examination, rheumatologists need to keep the 
diagnosis open in evaluating patients who present with 
pain in multiple joints.
Application of recently developed 2010 American 
College of Rheumatology (ACR)/European League Against 
Rheumatism (EULAR) classification criteria for RA pro-
vided an opportunity to identify and treat those patients 
with early inflammatory arthritis who progress to future 
RA. The new 2010 criteria is a diagnostic tool with higher 
sensitivity and specificity compared to previous ACR 
1987 criteria. The new criteria are markedly more effec-
tive at detecting RA early on than were the former 1987 
criteria. However, it is unless they are employed judi-
ciously, many patients will be inappropriately labeled as 
having RA and subjected to treatments they don’t actually 
[2].
Paraneoplastic rheumatic disorders, one of categories of 
differential diagnosis from RA, are defined as rheumatic 
symptoms resulting from an underlying malignant dis-
ease, which is not directly related to a tumor or metastasis 
[3]. In Korea, there have been a few cases of paraneo-
plastic syndrome appearing as a form of arthritis reported 
and most of them are solid tumors such as ovarian cancer, 
pancreatic cancer, and metastatic adenocarcinoma of un-
known primary site [4-6]. However, hematologic malig-
nancy as an underlying disease is rarely reported.
Here we report a patient presenting with polyarthritis 
who was initially diagnosed as RA with satisfying 2010 
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Figure 1. Photographs of right 
hand showing polyarthritis at 
first visit (A) and improved ar-
thritis after 6 cycles of ritux-
imab, cyclophosphamide, dox-
orubicin, vincristine, and pre-
dnisone (R-CHOP) chemothe-
rapy (B).
criteria but treated unsuccessfully with disease-modify-
ing anti-rheumatic drugs (DMARDs) including metho-
trexate (MTX) and anti-tumor necrosis factor (TNF) 
agents. She was finally diagnosed with diffuse large B-cell 
lymphoma limited to the bone marrow and improved of 
arthritis with chemotherapy.
CASE REPORT
A 63-year-old woman visited our clinic with a complaint 
of symmetrical polyarthritis in the hands, wrists and feet.
History of present illness
Arthralgia first occurred in both hands, wrists, and 
knees at 4 months before first visit to our hospital. 
Initially, she had a mild fever, and treated by antibiotics 
according to pyelonephritis. She had visited other referral 
university hospital and had been seen with a rheu-
matologist. After performing full examinations including 
laboratory tests and imaging studies, she had been diag-
nosed as seronegative RA. She had been treated with con-
ventional DMARDs at least 3 months with combination 
of MTX, hydroxychloroquine, sulfasalazine, or leflunomide. 
Since there was no improvement in her symptoms, com-
bination therapy with MTX and etanercept was started. 
During use of DMARDs, sensorineural hearing loss was 
suddenly developed and high dose steroid treatment was 
added. Although DMARDs treatment was not showing 
satisfactory response, high dose steroid was effective for 
controlling her arthritis. When prednisolone dose was re-
duced to 15 mg daily; however, the arthritis deteriorated 
again. Her personal and family history was not specific.
Physical examination
Upon admission, the patient had a fever of 38.2oC, while 
her other vital signs were stable: heart rate, 90 beats/min; 
breathing rate, 20 breaths/min; and blood pressure, 
120/70 mmHg. The fever occurred mostly in the night 
time and was accompanied by the systemic symptom of 
cold sweat. However, there were no other subjective 
symptoms and no observable weight loss or lympha-
denopathy. Tests of the musculoskeletal system displayed 
edema and tenderness in the metacarpophalanges 
(MCP), proximal interphalanges (PIP), and distal inter-
phalanges (DIP) of all fingers and toes as well as other 
joints of shoulders, wrists, knees, and ankles (Figure 1A). 
One unusual finding was that the patient complained of 
more pain when pressure was applied to the tendon prox-
imal to the joints than when the joints themselves were 
pressed.
Laboratory test findings
In peripheral blood testing, the leukocyte count was 
4,200/mm3, hemoglobin level was 9.8 g/dL, and platelet 
count was 558,000/mm3, while no abnormal cells were 
observed in the initial test. But after a week, immature 
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Figure 3. Whole body bone 
scintigraphy at first visit. Both 
wrists, proximal interphalanges, 
distal interphalanges, and meta-
carpophalanges joints on hands
showed increased symmetric 
uptake and tarsometatarsal jo-
ints and metatarsophalangeal 
joins were also showed increas-
ed uptake.
Figure 2. T1-weighted magnetic
resonance imaging of right 
hand at first visit (A) and after 6 
cycles of rituximab, cyclophos-
phamide, doxorubicin, vincris-
tine, and prednisone (R-CHOP) 
chemotherapy (B). Tenosynovitis
of proximal interphalanges joints 
(white arrows) and bone ero-
sions at carpal bones (black ar-
rows) and metacarpophalanges 
joints (A) had been resolved af-
ter 6 cycles of R-CHOP chemo-
therapy (B).
myeloblasts account for nearly 2 percent are seen in pe-
ripheral blood testing. Biochemical test results were in 
the normal ranges at 21 U/L for aspartate amino-
transferase, 38 U/L for alanine aminotransferase, 16.2 
mg/dL for blood urea nitrogen, 0.8 mg/dL for creatinine, 
and 77 mL/min/1.73 m2 for the estimated glomerular fil-
tration rate. Serum tests were negative for both rheuma-
toid factor (RF) and anti-cyclic citrullinated peptide 
(CCP) antibody, and the C-reactive protein (CRP) level 
and the erythrocyte sedimentation rate (ESR) were ele-
vated at 6.0 mg/dL and 63 mm/h, respectively. Perinuclear 
skeleton type (1:80) was detected in an antinuclear anti-
body test, and no bacteria was found in blood and urine 
culture tests performed to investigate the fever.
Diagnostic imaging 
On simple radiography of the joints, soft tissue edema 
was observed around the knees and the PIP joints of both 
hands, and periarticular osteoporosis was observed, but 
no obvious erosion was seen. However, on magnetic reso-
nance imaging (MRI) of the right hand, multiple erosions 
were observed in the MCP joints and the wrist and syno-
vitis and edema were observed around the PIP and DIP. 
These findings are similar to those of RA (Figure 2A). On 
whole body bone scan, a symmetrical increased uptake 
was observed in the MCP, PIP and DIP joints on both 
hands (Figure 3). Symmetrical involvement of hands and 
feet was common manifestation of early RA, especially 
obvious inflammation of PIP joints of the fingers.
Diagnosis of lymphoma 
Although the diagnostic imaging results were relatively 
consistent with RA, paraneoplastic syndrome from hem-
atologic malignancy was strongly suspected because of 
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Figure 4. Bone marrow biopsy showed multiple lymphocytes
concentrated with the various features. Lymphoid cells are 
oval shape and high nucleus-cytoplasm ratio (H&E, ×400;
white arrow).
immature myeloblasts seen in peripheral blood testing, 
night-time fever and cold sweat like B symptoms. 
Therefore, a bone marrow biopsy was conducted to iden-
tify the hematologic disorder. On the bone marrow biop-
sy, there was a dense group of lymphocytes with diverse 
appearances in hematoxylin and eosin stain with 400 
magnification (Figure 4), and immunohistochemical 
staining showed that the biopsy sample was positive for 
CD79a, CD20, and BCL-2, finally, the patient was diag-
nosed with diffuse large B-cell lymphoma. A whole-body 
positron emission tomography computed tomography re-
vealed findings seen in lymphoma, including increased 
uptake of bone marrow, and spleen and increased size of 
axillary lymph node.
Treatment and clinical progress 
Intravenous methylprednisolone (62.5 mg/d) was ap-
plied on the first day of hospitalization. Antipyretics were 
not used, but fever detected until third day and then 
subsided. During hospitalization, steroid was ad-
ministered without any DMARD or biologic agents. For 
anticancer drugs, rituximab, cyclophosphamide, doxor-
ubicin, and vincristine (R-CHOP) was initiated, and pre-
dnisolone (100 mg/d) was administered. Steroid dose 
was gradually reduced: prednisolone (15 mg/d) was used 
during the sixth and final anti-cancer treatment.
During chemotherapy, the patient’s arthralgia and ede-
ma were resolved (Figure 1B). As 10 months later from 
remission arthralgia, follow-up MRI of the hands re-
vealed that the previously observed edema in the PIP 
joints and erosions in MCP joints were disappeared 
(Figure 2B). As follow-up bone marrow biopsy revealed 
no further findings of lymphoma, the prednisolone dose 
was reduced by half every 3 months, and has been stop-
ped since. The patient has been followed up as an out-
patient of hematology and rheumatology department; she 
has not shown any recurrence of the arthritis and bone 
erosion in X-ray. She maintained seroconversion of ESR, 
CRP, negative finding of RF and anti-CCP antibodies for 
approximately 1 year since stopping steroid and DMARDs.
DISCUSSION
RA causes inflammation in the joint areas resulting in 
arthralgia and swelling characterized by morning stiff-
ness that lasts less than one hour. It mostly occurs sym-
metrically, and the main sites of invasion are the PIP, MCP, 
wrist, knee, and elbow joints. Although systemic fever is 
rare, high activity can cause a slight fever that is some-
times accompanied by symptoms like fatigue and pan-
talgia.
The above-mentioned case had features similar to those 
of RA including symmetrical polyarthritis and invasion of 
the PIP, MCP, and knee joints. When the 2010 criteria for 
RA diagnosis was applied to the present case, RA could be 
diagnosed in cases of invasions in ＞10 small joints, neg-
ative RF and anti-CCP antibodies, elevated inflammatory 
markers, and a duration of more than six weeks, corre-
sponding to a total of seven points [7]. Therefore, an ini-
tial diagnosis of RA by a rheumatologist was inevitable.
However, there was a no response to various DMARDs 
or anti-TNF agents, the patient was only responsive to 
steroids; this matter requires different diagnosis. In other 
words, if a patient is viewed only in terms of the RA classi-
fication criteria, the possibility polyarthritis caused by 
other underlying diseases could be underestimated. The 
findings in the present case of multiple involvements of 
the DIP joints accompanied by systemic symptoms such 
as intermittent night time fever were not typical symp-
toms of RA. These findings suggest that the risk of ac-
companied paraneoplastic syndrome is higher than that 
of RA.
A paraneoplastic syndrome is symptoms that are the 
consequences of cancer in the body but that unlike mass 
effect is not due to the local presence of cancer cells. 
These phenomena are mediated by humoral factors by 
hormones or cytokines excreted by tumor cells or by an 
immune response against the tumor. Typical features of 
paraneoplastic rheumatic syndrome are asymmetrical ar-
thritis, negative finding of RF, elderly patients aged less 
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than 50 years, and systemic symptoms such as fever, 
weight loss, and night sweat. But various symptoms are 
appeared in paraneoplastic rheumatic syndrome, espe-
cially symmetric arthralgia mimics RA in other study and 
cases [5,8].
As patients with rheumatic disease have a higher in-
cidence of certain malignant lymphoma compared to 
healthy people, it is necessary to check whether rheu-
matic disease is involved, even when paraneoplastic syn-
drome is suspected. In particular, lymphoma is known to 
occur twice as frequently in patients with RA than in typi-
cal individuals [9], as shown in a study of patients who 
had RA for several years; lymphoma is known to be 
caused when accompanied by Epstein-Barr virus and 
when immunosuppressed agents such as azathioprine, 
MTX, and TNF inhibitor have been used for a long time 
[10,11]. For the patient in case, the duration of arthritis 
was not long and DMARDS had only been used for 3 
months. In particular, paraneoplastic syndrome was sup-
ported by the improvement in the lymphoma, which was 
no longer observed in follow-up bone marrow biopsy af-
ter anti-cancer therapy. She improved of the RA–like 
symptoms, such as the erosions on MRI, disappearance of 
joint pain and edema for 1 year after stopping the steroid 
treatment. Also, she maintained normal range of CRP, 
ESR, negative finding of RF and anti-CCP antibodies. 
Accordingly, the possibility of concurrent development of 
lymphoma with RA was considered low.
In conclusion, arthritic symptoms caused by paraneo-
plastic syndrome worsen as tumors progress and recur, 
treatment for the original tumor will usually improve the 
arthritic symptoms. Thus, delayed diagnosis can cause 
rapid deterioration in prognosis, thus an accurate diag-
nosis is considered critical. So we should be suspected the 
possibility of paraneoplastic syndrome in patients who 
met RA criteria, but resistant typical RA medication, had 
systemic symptoms like fever, night sweat or weight loss.
SUMMARY
Along with a discussion of the literature, here in we re-
port of a 63-year-old woman who was diagnosed with RA 
due to symmetric arthritis in the hands and feet and was 
treated appropriately but unsuccessfully. The patient was 
ultimately diagnosed with diffuse large B-cell lymphoma 
limited to the bone marrow with accompanying paraneo-
plastic syndrome.
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